- Home
- KIO vs NGNE Comparison
KIO vs NGNE Comparison
Compare KIO & NGNE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KIO
- NGNE
- Stock Information
- Founded
- KIO 2011
- NGNE 2003
- Country
- KIO United States
- NGNE United States
- Employees
- KIO 2400
- NGNE N/A
- Industry
- KIO Investment Managers
- NGNE Biotechnology: Pharmaceutical Preparations
- Sector
- KIO Finance
- NGNE Health Care
- Exchange
- KIO Nasdaq
- NGNE Nasdaq
- Market Cap
- KIO 506.5M
- NGNE 213.2M
- IPO Year
- KIO N/A
- NGNE N/A
- Fundamental
- Price
- KIO $12.55
- NGNE $20.63
- Analyst Decision
- KIO
- NGNE Strong Buy
- Analyst Count
- KIO 0
- NGNE 7
- Target Price
- KIO N/A
- NGNE $41.86
- AVG Volume (30 Days)
- KIO 136.5K
- NGNE 225.2K
- Earning Date
- KIO 01-01-0001
- NGNE 08-08-2025
- Dividend Yield
- KIO 10.82%
- NGNE N/A
- EPS Growth
- KIO N/A
- NGNE N/A
- EPS
- KIO N/A
- NGNE N/A
- Revenue
- KIO N/A
- NGNE $925,000.00
- Revenue This Year
- KIO N/A
- NGNE N/A
- Revenue Next Year
- KIO N/A
- NGNE N/A
- P/E Ratio
- KIO N/A
- NGNE N/A
- Revenue Growth
- KIO N/A
- NGNE N/A
- 52 Week Low
- KIO $10.52
- NGNE $6.88
- 52 Week High
- KIO $13.59
- NGNE $74.49
- Technical
- Relative Strength Index (RSI)
- KIO 67.83
- NGNE 58.85
- Support Level
- KIO $12.50
- NGNE $19.01
- Resistance Level
- KIO $12.58
- NGNE $20.80
- Average True Range (ATR)
- KIO 0.06
- NGNE 1.61
- MACD
- KIO -0.00
- NGNE 0.24
- Stochastic Oscillator
- KIO 80.00
- NGNE 91.36
About KIO KKR Income Opportunities Fund
KKR Income Opportunities Fund operates as a closed-end registered management investment company. It seeks to generate a high level of current income, with a secondary objective of capital appreciation. The company invests in the portfolio of loans and fixed-income instruments of U.S. and non-U.S. issuers. The company will invest at least 80% of its Managed Assets in loans and fixed-income instruments or other instruments, including derivative instruments, with similar economic characteristics under normal market conditions.
About NGNE Neurogene Inc.
Neurogene Inc is a clinical-stage biotechnology company committed to overcoming the limitations of neurological diseases into treatable conditions, by harnessing its proprietary transgene regulation technology, EXACTTM (Expression Attenuation via Construct Tuning). It is building a differentiated product portfolio of genetic medicines for rare neurological diseases with high unmet needs. The drug candidates in the company's product pipeline include NGN-401, which is in development for the treatment of Rett syndrome, using its EXACT platform, and NGN-101, a non-EXACT, conventional gene therapy development candidate for the treatment of CLN5 Batten disease, designed to deliver the CLN5 gene and packaged in an AAV9 capsid.